Unithroid (Levothyroxine Sodium) Patent Expiration, LOE Window & CMS Spending

Unithroid (Levothyroxine Sodium) by Jerome Stevens: Off-Patent Genericized (AB Competition), 7 AB generics, $5.3M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJerome Stevens
FDA Application & PathwayN021210 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$5.3M
2024 Medicare Part D Spend$4.1M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 30.3% 2-yr change)